2,4,6-tri(tert-butyl)-1,3,5-triazine | 56382-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2,4,6-tri(tert-butyl)-1,3,5-triazine
• 英文别名: 2,4,6-tri-tert-butyl-[1,3,5]triazine；Tri-tert-butyl-s-triazin；2,4,6-Tritert-butyl-1,3,5-triazine
• CAS: 56382-55-9
• 化学式: C₁₅H₂₇N₃
• 分子量: 249.399
• InChiKey: VRBLCQOCHIBIBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  三甲基乙腈 生成 2,4,6-tri(tert-butyl)-1,3,5-triazine
  参考文献：
  名称：

  JARRE W.; BIENICK D.; KORTE F., TETRAHEDRON , 1975, 31, NO 6, 619-623

  摘要：

  DOI：

文献信息

• Piperazinyl-Pyridine Analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20080045525A1

  公开（公告）日：2008-02-21

  Piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to. modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了Piperazinyl-pyridine类似物，其化学式为：其中变量如本文所述。此类化合物是配体，可用于体内或体外调节特定受体活性，并在治疗与人类、家畜伴侣动物和家畜动物的病理性受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的配体使用方法。
• ADDITIVE FOR OILS AND LUBRICANT CONTAINING THE SAME
  申请人：Hiyoshi Satoshi

  公开号：US20100286008A1

  公开（公告）日：2010-11-11

  An additive for oils that is capable of imparting oils such as lubricant base oils or fuel oils with superior wear resistance properties or superior friction resistance properties and the like are provided. The additive for oils comprising a compound represented by formula (I): [Chemical Formula 1] (A) m -W—(B) n (I) wherein m represents an integer of 0 to 4, n represents an integer of 2 to 6, A represents hydroxy or amino, W represents hydrocarbon or the like, and B represents formula (II): wherein a represents 0 or 1, X represents an oxygen atom or NH, Y represents OR 1 or NHR 2 (wherein R 1 and R 2 each represent alkyl optionally having one or more substituents or the like), and Z 1 and Z 2 each represent a hydrogen atom, NR 3 R 4 (wherein R 3 and R 4 each represent alkyl optionally having one or more substituents or the like) or the like, and the like are provided.

  提供了一种用于油的添加剂，能够赋予润滑基础油或燃料油等油类具有优越的耐磨性能或优越的摩擦阻力性能等。该油添加剂包括以下式子所表示的化合物：[化学式1] (A)m-W—(B)n(I)，其中，m表示0到4的整数，n表示2到6的整数，A表示羟基或氨基，W表示烃基或类似物，B表示以下式子：[化学式2]其中，a表示0或1，X表示氧原子或NH，Y表示OR1或NHR2（其中，R1和R2分别表示有机基，可选地具有一个或多个取代基或类似物），Z1和Z2分别表示氢原子，NR3R4（其中，R3和R4分别表示有机基，可选地具有一个或多个取代基或类似物）或类似物。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：Charmot Dominique

  公开号：US20120263670A1

  公开（公告）日：2012-10-18

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和方法，用于治疗与液体潴留或盐过载相关的疾病，如心力衰竭（特别是充血性心力衰竭）、慢性肾脏病、终末期肾脏病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂引起的液体潴留。本公开还涉及化合物和方法，用于治疗高血压。本公开还涉及化合物和方法，用于治疗胃肠道疾病，包括治疗或减轻与胃肠道疾病相关的疼痛。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER
  申请人：Ardelyx, Inc.

  公开号：US20150190389A1

  公开（公告）日：2015-07-09

  The present disclosure is directed to compounds of the structure (X): CoreL-NHE) n (X) wherein: n is 2 or 3; NHE has the structure wherein: R 1 is H or —SO 2 —NR 7 R 8 —; R 2 is selected from H, —NR 7 (CO)R 8 , —SO 2 —NR 7 R 8 — and —NR 7 R 8 ; R 3 is hydrogen; R 7 is hydrogen; R 8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(═O)—, —NHC(═O)NH— and —NHSO 2 —; and Y is selected from the group consisting of a bond, optionally substituted C 1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH 2 ) 1-6 O(CH 2 ) 1-6 —, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.

  本公开涉及结构为（X）：CoreL-NHE)n（X）的化合物，其中：n为2或3；NHE具有以下结构：其中：R1为H或—SO2—NR7R8—；R2选自H，—NR7（CO）R8，—SO2—NR7R8—和—NR7R8；R3为氢；R7为氢；R8为连接到L的键；L为多聚乙二醇连接剂；Core具有以下结构：其中：X选自由键，—O—，—NH—，NHC（═O）—，—NHC（═O）NH—和—NHSO2—；Y选自键，可选择性地取代的C1-6烷基，可选择性地取代的苯，吡啶基，聚乙二醇连接剂和—（CH2）1-6O（ ）1-6—，以及使用这种化合物治疗肠易激综合征、慢性肾脏病和终末期肾脏疾病的方法。
• ORGANIC MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME
  申请人：LUMINESCENCE TECHNOLOGY CORP.

  公开号：US20160190472A1

  公开（公告）日：2016-06-30

  The present invention discloses an novel organic material is represented by the following formula (A) and organic EL device using the organic material as hole blocking layer (HBL), electron transport layer (ETL) or phosphorescent host can efficiently lower driving voltage, lower power consumption and increase the efficiency. The same definition as described in the present invention.

  本发明揭示了一种新型有机材料，其由以下公式（A）表示，以该有机材料作为阻挡层（HBL）、电子传输层（ETL）或磷光主机的有机EL器件可以有效降低驱动电压、降低功耗并提高效率。与本发明中所述的定义相同。